Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Mariam Obaid; Ibrahim A. Abdelazim; Mohannad AbuFaza; Hanan S. Al-Khatlan; Aliaa M. Al-Tuhoo; Fawziah H. Alkhaldi

doi:10.5114/pm.2023.126347

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2023
vol. 22

Send email

Copy url:

abstract:

Original paper

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Mariam Obaid

¹

,

Ibrahim A. Abdelazim

^{1, 2}

,

Mohannad AbuFaza

¹

,

Hanan S. Al-Khatlan

¹

,

Aliaa M. Al-Tuhoo

¹

,

Fawziah H. Alkhaldi

³

Department of Obstetrics and Gynaecology, Ahmadi Hospital, Kuwait Oil Company (KOC), Ahmadi, Kuwait
Department of Obstetrics and Gynaecology, Ain Shams University, Cairo, Egypt
Department of Internal Medicine and Clinical Haematology, Farwaniya Hospital, Kuwait City, Kuwait

Menopause Rev 2023; 22(1): 16-20

DOI: https://doi.org/10.5114/pm.2023.126347

Online publish date: 2023/03/31

View full text Get citation

PlumX metrics:

Introduction
To evaluate the efficacy of ferric carboxy maltose (FCM) in the treatment of iron deficiency/iron deficiency anaemia (ID/IDA) during pregnancy.

Material and methods
Pregnant women ≥ 20 years old diagnosed with ID (serum ferritin < 15 µg/l) and moderate IDA were included in this study for correction of their ID/IDA. The participants received an FCM infusion for correction of their ID/IDA. The pre-treatment ferritin, haemoglobin (Hb), and red blood cell (RBC) indices were compared with the 6- and 12-week post-treatment values to evaluate the efficacy of FCM in the treatment of ID/IDA during pregnancy.

Results
The pre-treatment ferritin and Hb significantly increased from 10.3 ±2.3 µg/l and 7.99 ±0.6 g/dl, respectively, to 139.5 ±1.9 and 14.04 ±0.45, respectively, 6-weeks after FCM infusion (p = 0.02 and 0.001, respectively), and to 128.9 ±1.7 and 13.02 ±0.5, respectively, 12-weeks after FCM infusion (p = 0.0008 and 0.02, respectively). In addition, the pre-treatment RBCs mean corpuscular volume and RBCs mean corpuscular haemoglobin (MCH) significantly increased from 72.02 ±3.5 fl and 23.9 ±1.9 pg, respectively, to 90.6 ± 2.8 fl and 29.98 ±1.5 pg, respectively, 6 weeks after FCM infusion (p = 0.01 and p = 0.007, respectively), and to 89.5 ±2.9 fl and 30.2 ±1.5 pg, respectively, 12 weeks after FCM infusion (p = 0.02 and 0.007 respectively).

Conclusions
The ferric carboxy maltose was safe and effective for the treatment of ID/IDA during pregnancy within 6 weeks. The serum ferritin and Hb levels and the RBC indices remained significantly high 12 weeks after FCM infusion compared to the pre-treatment values.

keywords:

Efficacy of ferric carboxy maltose in treatment of iron deficiency/iron deficiency anaemia during pregnancy

Mariam Obaid 1 , Ibrahim A. Abdelazim 1, 2 , Mohannad AbuFaza 1 , Hanan S. Al-Khatlan 1 , Aliaa M. Al-Tuhoo 1 , Fawziah H. Alkhaldi 3

ferric carboxy maltose (FCM), iron deficiency (ID), iron deficiency anaemia (IDA), pregnancy

Mariam Obaid

¹

,

Ibrahim A. Abdelazim

^{1, 2}

,

Mohannad AbuFaza

¹

,

Hanan S. Al-Khatlan

¹

,

Aliaa M. Al-Tuhoo

¹

,

Fawziah H. Alkhaldi

³